Back to Search Start Over

Liver function and portal‐systemic shunting quantified by the oral cholate challenge test and risk for large oesophageal varices.

Authors :
Hassanein, Tarek
Keaveny, Andrew P.
Mantry, Parvez
Smith, Alastair D.
McRae, Michael P.
Kittelson, John
Helmke, Steve
Everson, Gregory T.
Bambha, Kiran
Fuchs, Michael
Gilroy, Richard K.
Reddy, K. Rajender
Shiffman, Mitchell L.
Rahimi, Robert S.
Hellstern, Paul A.
Hill, John M.
Kayali, Zeid
Denham, Doug
Qureshi, Kamran
Smith, Brian
Source :
Alimentary Pharmacology & Therapeutics; Jul2024, Vol. 60 Issue 2, p246-256, 11p
Publication Year :
2024

Abstract

Summary: Background: The quantitative HepQuant SHUNT test of liver function and physiology generates a disease severity index (DSI) that correlates with risk for clinical complications, such as large oesophageal varices (LEVs). A derivative test, HepQuant DuO, generates an equivalent DSI and simplifies testing by requiring only oral administration of the test solution and two blood samples at 20 and 60 min. Aims: Since the DSIs measured from DuO and SHUNT are equivalent, we compared the diagnostic performance for large oesophageal varices (LEVs) between the DSIs measured from DuO and SHUNT tests. Methods: This study combined the data from two prospectively conducted US studies: HALT‐C and SHUNT‐V. A total of 455 subjects underwent both the SHUNT test and esophagogastroduodenoscopy (EGD). Results: DSI scores correlated with the probability of LEVs (p < 0.001) and demonstrated a stepwise increase from healthy lean controls without liver disease to subjects with chronic liver disease and no, small or large varices. Furthermore, a cutoff of DSI ≤ 18.3 from DuO had a sensitivity of 0.98 (missing only one case) and, if applied to the endoscopy (EGD) decision, would have prevented 188 EGDs (41.3%). The AUROC for DSI from DuO did not differ from that of the reference SHUNT test method (0.82 versus 0.81, p = 0.3500). Conclusions: DSI from HepQuant DuO links liver function and physiology to the risk of LEVs across a wide spectrum of patient characteristics, disease aetiologies and liver disease severity. DuO is minimally invasive, easy to administer, quantitative and may aid the decision to avoid or perform EGD for LEVs. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
02692813
Volume :
60
Issue :
2
Database :
Complementary Index
Journal :
Alimentary Pharmacology & Therapeutics
Publication Type :
Academic Journal
Accession number :
178095672
Full Text :
https://doi.org/10.1111/apt.18054